Boston Scientific Target of Unusually High Options Trading (NYSE:BSX)

Boston Scientific Corporation (NYSE:BSX) saw some unusual options trading on Thursday. Stock traders acquired 35,604 put options on the company. This is an increase of 161% compared to the typical daily volume of 13,616 put options.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Strategic rationale — the acquisition gives BSX immediate scale in mechanical thrombectomy and neurovascular devices, expanding its cardiovascular portfolio and entry into fast‑growing vascular segments, which could drive medium‑term revenue and market-share gains. Boston Scientific announces agreement to acquire Penumbra, Inc.
• Neutral Sentiment: Complementary M&A and product wins — recent smaller deals (Valencia Technologies) and regulatory wins (Farapoint PFA catheter, CE mark for coils) continue to diversify growth engines but are incremental compared with the Penumbra transaction. Boston Scientific to buy incontinence device maker Valencia
• Neutral Sentiment: Analyst views supportive — some analysts reiterated buy ratings and highlighted long‑term upside from the company’s EP and electro‑physiology franchise, partially offsetting integration concerns. Farapoint PFA Approval Strengthens EP Ecosystem and Supports Buy Rating
• Negative Sentiment: Market reaction and financing concerns — investors sold BSX as the deal is large (~$14.5B enterprise value), raising near‑term concerns about dilution, integration costs and leverage; Penumbra shares rose sharply while BSX declined on the news. Boston Scientific to acquire Penumbra in $14.5B deal
• Negative Sentiment: Bearish options flow — unusually large put buying (≈35,600 puts, ~161% above typical daily volume) signals elevated short‑term investor hedging or bearish speculation, adding downward pressure.
• Negative Sentiment: Regulatory / litigation flags for target — shareholder‑investigation notices related to Penumbra were circulated, which could add legal/transaction risk or distract management during integration. BRODSKY & SMITH SHAREHOLDER UPDATE

Analysts Set New Price Targets

Several research analysts have recently commented on the company. Wall Street Zen downgraded Boston Scientific from a “buy” rating to a “hold” rating in a report on Saturday, December 20th. Royal Bank Of Canada boosted their price objective on Boston Scientific from $125.00 to $130.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 17th. Robert W. Baird increased their target price on Boston Scientific from $123.00 to $128.00 and gave the stock an “outperform” rating in a report on Wednesday, October 1st. Canaccord Genuity Group lowered their target price on Boston Scientific from $132.00 to $131.00 and set a “buy” rating for the company in a research note on Wednesday, December 17th. Finally, BTIG Research reiterated a “buy” rating and set a $132.00 price target on shares of Boston Scientific in a research report on Friday, November 21st. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $125.21.

Insider Activity

In related news, EVP Arthur C. Butcher sold 17,313 shares of the business’s stock in a transaction on Monday, December 1st. The stock was sold at an average price of $101.55, for a total value of $1,758,135.15. Following the sale, the executive vice president owned 23,600 shares of the company’s stock, valued at $2,396,580. The trade was a 42.32% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction on Monday, November 3rd. The stock was sold at an average price of $99.47, for a total value of $4,973,500.00. Following the transaction, the executive vice president owned 178,342 shares of the company’s stock, valued at $17,739,678.74. This represents a 21.90% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 93,095 shares of company stock worth $9,305,450. Company insiders own 0.50% of the company’s stock.

Institutional Trading of Boston Scientific

Institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. increased its holdings in Boston Scientific by 0.8% in the third quarter. Vanguard Group Inc. now owns 138,249,447 shares of the medical equipment provider’s stock valued at $13,497,294,000 after purchasing an additional 1,115,337 shares during the last quarter. State Street Corp grew its position in shares of Boston Scientific by 1.1% during the 2nd quarter. State Street Corp now owns 65,191,864 shares of the medical equipment provider’s stock worth $7,002,258,000 after buying an additional 713,379 shares during the period. Geode Capital Management LLC increased its stake in shares of Boston Scientific by 2.0% in the 2nd quarter. Geode Capital Management LLC now owns 32,424,982 shares of the medical equipment provider’s stock valued at $3,466,320,000 after acquiring an additional 622,602 shares during the last quarter. Norges Bank bought a new stake in shares of Boston Scientific in the 2nd quarter valued at about $2,089,937,000. Finally, Invesco Ltd. raised its position in shares of Boston Scientific by 0.7% in the 3rd quarter. Invesco Ltd. now owns 16,963,344 shares of the medical equipment provider’s stock valued at $1,656,131,000 after acquiring an additional 111,826 shares during the period. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Trading Down 4.0%

Boston Scientific stock traded down $3.75 during mid-day trading on Thursday, hitting $90.00. The stock had a trading volume of 27,904,943 shares, compared to its average volume of 7,056,339. The stock has a 50-day simple moving average of $97.14 and a two-hundred day simple moving average of $100.46. The company has a current ratio of 1.51, a quick ratio of 0.96 and a debt-to-equity ratio of 0.47. The stock has a market capitalization of $133.41 billion, a PE ratio of 48.13, a P/E/G ratio of 1.66 and a beta of 0.67. Boston Scientific has a 12 month low of $85.98 and a 12 month high of $109.50.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.71 by $0.04. Boston Scientific had a net margin of 14.43% and a return on equity of 19.46%. The company had revenue of $5.07 billion for the quarter, compared to the consensus estimate of $4.97 billion. During the same period in the prior year, the company posted $0.63 EPS. The company’s revenue was up 20.3% compared to the same quarter last year. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. As a group, sell-side analysts forecast that Boston Scientific will post 2.85 EPS for the current year.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.